Back to top
more

Omeros (OMER)

(Delayed Data from NSDQ)

$3.31 USD

3.31
1,209,780

-0.86 (-20.62%)

Updated May 16, 2024 04:00 PM ET

After-Market: $3.30 -0.01 (-0.30%) 4:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for OMER

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Omeros Corporation [OMER]

Reports for Purchase

Showing records 381 - 400 ( 423 total )

Company: Omeros Corporation

Industry: Medical - Products

Record: 381

05/19/2011

Company Report

Pages: 3

Advancing Two Product Candidates into Phase 3 Trials

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 382

05/19/2011

Daily Note

Pages: 3

Advancing Two Product Candidates into Phase 3 Trials

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 383

05/13/2011

Company Report

Pages: 8

Q1 Cash Of $43.6 Million Can Last Into Q2 2012 Which Could Include Potential Partnerships.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 384

05/13/2011

Company Report

Pages: 8

We Project Q1 Cash Of $43.6 Million Can Last Into Q2 2012 Which Could Include Potential Partnerships And Data Releases.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 385

04/01/2011

Daily Note

Pages: 9

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 386

04/01/2011

Company Report

Pages: 5

Failure in Knee Surgery Phase 3 Trials - Lowering Rating to Market Perform

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 387

04/01/2011

Company Report

Pages: 3

Failure in Knee Surgery Phase 3 Trials - Lowering Rating to Market Perform

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 388

03/31/2011

Company Report

Pages: 8

Reducing Fair Value Due to Negative OMS103HP/ACL Phase 3.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 389

03/25/2011

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of March 27

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 390

03/24/2011

Daily Note

Pages: 4

MORNING SUMMARY.

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 391

03/23/2011

Company Report

Pages: 8

Raising Fair Value to $18 Due to Positive OMS302 Phase 2b Results.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 392

03/23/2011

Daily Note

Pages: 3

Impressive Data in Eye Surgery, ACL is up Next

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 393

03/23/2011

Daily Note

Pages: 3

Impressive Data in Eye Surgery, ACL is up Next

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 394

03/15/2011

Company Report

Pages: 8

Q4 Financials Were Uneventful. Imminent Release of Phase 3 Clinical Data Could Result in Significant Upside.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 395

03/04/2011

Industry Report

Pages: 5

LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of March 6

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 396

03/02/2011

Daily Note

Pages: 5

Orphan GPCRs Unlock May Lead to Lucrative Partnership

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 397

02/23/2011

Daily Note

Pages: 8

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 398

02/22/2011

Daily Note

Pages: 3

Expansion Of The PDE7 Platform Licensing Agreement

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 399

02/04/2011

Industry Report

Pages: 19

MONTHLY PORTFOLIO UPDATE - ELEMER PIROS AND BORIS PEAKER

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 50.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 400

01/07/2011

Daily Note

Pages: 4

2010 RECAP & 2011 PREVIEW

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party